Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Operational and Trading Update

21 Jan 2021 07:00

RNS Number : 3774M
Zotefoams PLC
21 January 2021
 

Zotefoams plc

("Zotefoams" or "Group")

 

Operational and Trading Update

 

21 January 2021 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the Group's financial year ended 31 December 2020 (unaudited) ahead of the publication of its preliminary results on Tuesday 23 March 2021.

Zotefoams is pleased to report that the strong second half trading momentum highlighted at the time of the Group's third quarter update was maintained for the remainder of the year, resulting in record six-months sales and more than reversing the decline in the first half. As a result, full year Group revenue was slightly above that of the previous year, in line with current market expectations. Full year trends for the specific business units were as follows:

· HPP sales increased by over 10%

o Footwear sales grew in excess of 65%, with strong momentum from new products and projects in the second half, and now represent approximately 25% of Group revenue;

o ZOTEK® fluoropolymer foam revenue, where the main market is aviation, declined by approximately 50%;

o T-FIT® technical insulation sales grew modestly, despite encouraging levels of demand, with COVID-related delays in India negatively impacting growth versus our expectations in the period;

· AZOTE® polyolefin sales were in line with the previous year. The business experienced a decline of approximately 20% in sales to its traditional markets, which are mainly in industrial applications, although there was notable recovery in demand from these sectors in the fourth quarter. This decline was offset by project-related PPE sales to UK Government programmes which ended late in the year, as expected;

· MuCell Extrusion sales declined by over 40%, mainly in equipment, impacted by the travel restrictions imposed by COVID-19 and a refocus of management time towards its ReZorce® mono-material barrier packaging technology. During 2020, the Group has further progressed the development of the ReZorce product.

Whilst the improving backdrop in the second half has enabled the Group to begin reinstating investment into its long-term growth drivers, operational performance has been strong and, consequently, adjusted profit before tax and exceptional items for the year ending 31 December 2020 is anticipated to be at the top end of market expectations. Alongside this, solid cash generation has returned the leverage ratio (net debt to EBITDA) closer to 2x.

Commissioning of Zotefoams' third foam manufacturing factory, in Poland, is expected early in February. Delivered on budget, but purposely delayed due to lower demand caused by COVID-19, this facility completes the planned spending on major capital projects, increases Group capacity and is well-positioned to generate and support demand growth.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"We are pleased to report robust figures in what have been very challenging conditions. The Group has demonstrated not only the breadth and resilience in demand for the Group's differentiated technology, but also the organisation's flexibility to realign commercial and operational activity quickly and effectively. As a result, we have successfully managed to grow sales, provide operational continuity for our customers and retain a strong financial position.

"The adverse impact of COVID-19 encountered during 2020 across most markets, as well as the risk of operational disruption, will continue into the current year, although I believe Zotefoams is well positioned to address these challenges. Our focus on the health and safety of employees globally and all visitors to our sites is our priority and continues to be delivered through well-established procedures.

"We have been encouraged by the recovery momentum in the general industrial markets for AZOTE® foams through the end of 2020 and, whilst sales to PPE applications are expected to be minimal in the current year, this positive momentum, alongside the continuing structural growth in HPP segments such as footwear and T-FIT® technical insulation, provides a strong platform for progress in 2021.

 

"With tariff-free trading, the outcome from Brexit negotiations has been as good as we might have expected, although delays at ports are currently reducing transport availability and causing what we believe will be short-term disruptions to our business.

"Whilst the macroeconomic climate remains uncertain and challenging, we believe Zotefoams has a strong portfolio of opportunities, a clear strategy and is well-invested in capacity to deliver growth."

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

 

Gary McGrath, Group CFO

 

 

 

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

 

About Zotefoams plc

 

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam manufacturing site, in Poland, is planned to begin operations early in 2021.

 

www.zotefoams.com 

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEIFWSEFSEEF
Date   Source Headline
27th May 20264:06 pmRNSNotification of Transactions of Directors/PDMRs
27th May 20264:00 pmRNSResult of the 2026 Annual General Meeting
27th May 20267:00 amRNSTrading Update
12th May 20267:00 amRNSInvestor Presentation via Investor Meet Company
11th May 20267:00 amRNSNotification of Transactions of Directors/PDMRs
7th May 20267:00 amRNSIssue of Equity
30th Apr 20261:00 pmRNSFinal Dividend Payment Date
27th Apr 20267:00 amRNS2025 Annual Report and Notice of the 2026 AGM
15th Apr 20269:24 amRNSNotification of Transactions of Directors/PDMRs
31st Mar 20266:06 pmRNSHolding(s) in Company
25th Mar 20269:35 amRNSNotification Of Transactions Of Directors/PDMRs
17th Mar 20267:00 amRNSPreliminary Results
17th Mar 20267:00 amRNSPreliminary Results
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Mar 20267:00 amRNSPreliminary results presentation
11th Mar 20267:00 amRNSPreliminary results presentation
13th Feb 20267:00 amRNSNotification Of Transactions Of Directors/PDMRs
27th Jan 20267:00 amRNSChange of Registered Office Address
22nd Jan 20267:00 amRNSTrading Update
15th Jan 20269:57 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
18th Nov 202512:39 pmRNSAcquisition of Overseas Konstellation Company S.A.
12th Nov 20254:12 pmRNSNotification Of Transactions Of Directors/PDMRs
4th Nov 20257:00 amRNSTrading Update
24th Oct 20257:00 amRNSNon-Executive Directorate Changes
14th Oct 20252:54 pmRNSNotification Of Transactions Of Directors/PDMRs
9th Oct 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Sep 20254:25 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
22nd Sep 20252:33 pmRNSGroup CFO succession
12th Sep 20255:11 pmRNSNotification Of Transactions Of Directors/PDMR
28th Aug 20257:00 amRNS-RInnovation Initiatives and Executive Appointment
19th Aug 20252:16 pmRNSHolding(s) in Company
14th Aug 20256:19 pmRNSHolding(s) in Company
12th Aug 20252:57 pmRNSNotification Of Transactions Of Directors/PDMR
8th Aug 20257:00 amRNSHolding(s) in Company
7th Aug 202512:14 pmRNSHolding(s) in Company
5th Aug 20257:01 amRNSJoint Venture Agreement and Executive Appointment
5th Aug 20257:00 amRNSInterim Results
29th Jul 202511:01 amRNSInvestor Presentation via Investor Meet Company
14th Jul 20252:51 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Jun 20252:41 pmRNSNotification of Transactions of Directors/PDMRs
10th Jun 20254:13 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd May 202512:30 pmRNSResult of the 2025 Annual General Meeting
22nd May 20257:00 amRNSTrading Update
13th May 202512:05 pmRNSNotification Of Transactions Of Directors/PDMRs
1st May 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Apr 20257:00 amRNSGroup CFO succession
24th Apr 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
22nd Apr 20257:00 amRNS2024 Annual Report & Notice of 2025 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.